Generation of an IL2 knock-in human induced pluripotent stem cell line by CRISPR/Cas9 system

Interleukin-2 (IL2) is a critical cytokine that drives T-cell proliferation, activates NK cells, and holds significant therapeutic value. Its established clinical importance in cancer immunotherapy lies in sustaining the expansion, persistence, and effector function of adoptive cell therapies. Here, we established a stable IL2 knock-in human induced pluripotent stem cell (iPSC) line via CRISPR/Cas9 technology. This engineered line constitutively secretes IL2, maintains a normal karyotype, and retains typical pluripotent characteristics, including gene expression and in vivo differentiation potential. It thus provides a reliable model for studying IL2 signaling, immune crosstalk, and therapeutic screening